Arda Therapeutics Secures $43M Series A Funding to Pioneer ADCs for Fibrotic Diseases
Arda Therapeutics, Series A Funding, Fibrotic Diseases, Antibody-Drug Conjugates (ADCs), Eli Lilly, Andreessen Horowitz (a16z)
Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials
Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.
Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells
Astellas, Universal Cells, cell therapy, regenerative medicine, Japan research site, allogeneic cell therapy
Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows
Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing
2024 Nobel Prize in Chemistry Awarded to Trio for Groundbreaking Protein Research
Nobel Prize in Chemistry 2024, Protein Structure Prediction, Computational Protein Design, David Baker, Demis Hassabis, John Jumper
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination
Pfizer CEO Albert Bourla to Engage with Activist Investor Starboard Value on Strategic Overhaul
Pfizer, Albert Bourla, Starboard Value, activist investor, pharmaceutical industry, strategic overhaul, post-COVID challenges
Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases
Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
FDA Halts Kezar’s Lupus Nephritis Trial Due to Safety Concerns Following Four Patient Deaths
FDA, Kezar Life Sciences, lupus nephritis, zetomipzomib, clinical hold, patient deaths, safety concerns
FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Ahead of Advisory Committee Meeting
FDA, Stealth BioTherapeutics, elamipretide, Barth syndrome, ultra-rare disease, advisory committee meeting, drug approval, efficacy concerns